The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage
Open accessAbstract
Ab-dependent cellular cytotoxicity (ADCC) is usually considered an important mechanism of action for immunotherapy with human IgG1 but not IgG2 Abs. The epidermal growth factor receptor (EGF-R) Ab panitumumab represents the only human IgG2 Ab approved for immunotherapy and inhibition of EGF-R signaling has been described as its principal mechanism of action. In this study, we investigated effector mechanisms of panitumumab compared with zalutumumab, an EGF-R Ab of the human IgG1 isotype. Notably, panitumumab was as effective as zalutumumab in recruiting ADCC by myeloid effector cells (i.e., neutrophils and monocytes) in contrast to NK cell-mediated ADCC, which was only induced by the IgG1 Ab. Neutrophil-mediated tumor cell killing could be stimulated by myeloid growth factors and was triggered via FcγRIIa. Panitumumab-mediated ADCC was significantly affected by the functional FcγRIIa-R131H polymorphism and was induced more effectively by neutrophils from FcγRIIa-131H homozygous donors than from -131R individuals. This polymorphism did not affect neutrophil ADCC induced by the IgG1 Ab zalutumumab. The in vivo activity of both Abs was assessed in two animal models: a high-dose model, in which signaling inhibition is a dominant mechanism of action, and a low-dose model, in which effector cell recruitment plays a prominent role. Zalutumumab was more effective than panitumumab in the high-dose model, reflecting its stronger ability to induce EGF-R downmodulation and growth inhibition. In the low-dose model, zalutumumab and panitumumab similarly prevented tumor growth. Thus, our results identify myeloid cell-mediated ADCC as a potent and additional mechanism of action for EGF-R–directed immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829
Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0463 · Cited by 521
Cited by
Tumor-associated neutrophils: friend or foe?
Fridlender, Z. G., & Albelda, S. M. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs123 · Cited by 699
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592
“These results raise the possibility that Treg cell depletion is also relevant to the activity of tremelimumab and that FcgR polymorphisms may contribute to its activity, since the CD32a-H131R polymorphism confers higher relative binding affinity to IgG2 (Bruhns et al., 2009; Sanders et al., 1995; Schneider-Merck et al…”
BackgroundResultInfluentialThe CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer
Matlung, H. L., Szilagyi, K., Barclay, N. A., & van den Berg, T. K. (2017) · Immunological Reviews · doi:10.1111/imr.12527 · Cited by 557
Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521
Self-citationTargeting the ERBB family in cancer: couples therapy
Tebbutt, N., Pedersen, M. W., & Johns, T. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3559 · Cited by 466
Neutrophils in Cancer: Two Sides of the Same Coin
Uribe-Querol, E., & Rosales, C. (2015) · Journal of Immunology Research · doi:10.1155/2015/983698 · Cited by 422
Optimal treatment for recurrent/metastatic head and neck cancer
Vermorken, J. B., & Specenier, P. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq453 · Cited by 383
Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
Centanni, M., Moes, D. J. A. R., Trocóniz, I. F., Ciccolini, J., & van Hasselt, J. G. C. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00748-2 · Cited by 355
Schaefer, G., Haber, L., Crocker, L. M., Shia, S., Shao, L., Dowbenko, D., Totpal, K., Wong, A., Lee, C. V., Stawicki, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.003 · Cited by 341
Ferris, R. L., Jaffee, E. M., & Ferrone, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6360 · Cited by 320
Srivastava, R. M., Lee, S. C., Andrade Filho, P. A., Lord, C. A., Jie, H.-B., Davidson, H. C., López-Albaitero, A., Gibson, S. P., Gooding, W. E., Ferrone, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2426 · Cited by 318
Lee, S. C., Srivastava, R. M., López-Albaitero, A., Ferrone, S., & Ferris, R. L. (2011) · Immunologic Research · doi:10.1007/s12026-011-8231-0 · Cited by 156
Garrido, G., Rabasa, A., Sánchez, B., López, M. V., Blanco, R., López, A., Hernández, D. R., Pérez, R., & Fernández, L. E. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003477 · Cited by 91
Targeting the insulin growth factor receptor 1
Arnaldez, F. I., & Helman, L. J. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.01.004 · Cited by 88
Delidakis, G., Kim, J. E., George, K., & Georgiou, G. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-082721-024500 · Cited by 87
Polymeric human Fc-fusion proteins with modified effector functions
Mekhaiel, D. N. A., Czajkowsky, D. M., Andersen, J. T., Shi, J., El-Faham, M., Doenhoff, M., McIntosh, R. S., Sandlie, I., He, J., Hu, J., et al. (2011) · Scientific Reports · doi:10.1038/srep00124 · Cited by 85
Kasper, S., Breitenbuecher, F., Reis, H., Brandau, S., Worm, K., Köhler, J., Paul, A., Trarbach, T., Schmid, K. W., & Schuler, M. (2013) · Oncogene · doi:10.1038/onc.2012.302 · Cited by 35
Alonso, V., Escudero, P., Fernández-Martos, C., Salud, A., Méndez, M., Gallego, J., Rodriguez, J.-R., Martín-Richard, M., Fernández-Plana, J., Manzano, H., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2018.05.004 · Cited by 10
Metadata
- Authors
- Schneider-Merck, T., Lammerts van Bueren, J. J., Berger, S., Rossen, K., van Berkel, P. H. C., Derer, S., Beyer, T., Lohse, S., Bleeker, W. K., Peipp, M., Parren, P. W. H. I., van de Winkel, J. G. J., Valerius, T., & Dechant, M.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-12-14
- Volume
- 184
- Issue
- 1
- Pages
- 512-520
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1930879408
- Cited by
- 222
- References
- 3
- FWCI
- 13.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.